Dergiler / Turkish journal of nephrology (Online) / 2022 / Cilt: 31 - Sayı: 3

Relationship Between Severity of Renal Amyloid Deposition and Clinical Outcomes in Non-AA Amyloidosis

Sayfa
202–208
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, patient survival is not significantly different according to Renal Amyloid Prognostic Score grade.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Renal involvement is a common manifestation of systemic amyloidosis.
📊
Temel Bulgular & Veri:Methods: This retrospective cohort study included 74 subjects with renal non-AA amyloidosis (52 light chain amyloidosis and 22 unclassified amyloidosis).
💡
Sonuç & Katkı:However, patient survival is not significantly different according to Renal Amyloid Prognostic Score grade.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Renal involvement is a common manifestation of systemic amyloidosis. Amyloid load can be predicted by histopathological grading of amyloid deposits in renal biopsy specimens. This study aimed to determine the relationship of renal amyloid deposition grade with clinical manifestations and outcomes in patients with biopsy-proven renal non-AA amyloidosis. Methods: This retrospective cohort study included 74 subjects with renal non-AA amyloidosis (52 light chain amyloidosis and 22 unclassified amyloidosis). Baseline characteristics and follow-up data were recorded. Pattern and quantity of amyloid deposition in glomeruli, interstitium, vessels, and tubulointerstitial changes were scored. Renal Amyloid Prognostic Score was obtained by addition of all scores and divided into 3 grades (Renal Amyloid Prognostic Score grades I, II, III). Results: In light chain amyloidosis group, the median follow-up was 11 (4-45) months. The baseline estimated glomerular filtration rate was significantly lower among patients with Renal Amyloid Prognostic Score grade III. Death-censored Renal survival was significantly lower among patients with Renal Amyloid Prognostic Score grade III. Renal Amyloid Prognostic Score grade III was a significant predictor of lower renal survival. Patient survival was not significantly different according to Renal Amyloid Prognostic Score grade. Receiving autologous stem cell transplantation treatment was associated with better patient survival. The type of amyloid could not be determined in 22 patients. In this group, baseline estimated glomerular filtration rate was significantly lower in patients with Renal Amyloid Prognostic Score grade III. Conclusions: In patients with light chain amyloidosis, baseline renal function is associated with Renal Amyloid Prognostic Score grade. Renal survival is significantly lower in patients with the highest Renal Amyloid Prognostic Score grade. However, patient survival is not significantly different according to Renal Amyloid Prognostic Score grade.

🔖

Bu Makaleye Atıf Yap

ŞEN, S., ÇELTİK, A., TÖZ, H., AŞÇI, G., KUMBARACI, B. S., SAYDAM, G., KARADAĞ, F. K., ÖZKAHYA, M. (2022). Relationship Between Severity of Renal Amyloid Deposition and Clinical Outcomes in Non-AA Amyloidosis. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 3, 202–208. https://ajindex.com/articles/609459

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003
  2. 349(6):583-596. [CrossRef] 2. Khalighi MA, Dean Wallace W, Palma-Diaz MF. Amyloid nephropathy. Clin Renal J. 2014
  3. 7(2):97-106. [CrossRef] 3. Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013
  4. 8(9):1515-1523. [CrossRef] 4. von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Röcken C. Prevalence and origin of amyloid in renal biopsies. Am J Surg Pathol. 2009
  5. 33(8):1198-1205. [CrossRef] 5. Tuglular S, Yalcinkaya F, Paydas S, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant. 2002
  6. 17(11):2003-2005. [CrossRef] 6. Sen S, Sarsik B. A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. Arch Pathol Lab Med. 2010
  7. 134(4):532-544. [CrossRef] 7. Dember LM. Amyloidosis-associated renal disease. J Am Soc Nephrol. 2006
  8. 17(12):3458-3471. [CrossRef] 8. Gertz MA, Leung N, Lacy MQ, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the renal. Nephrol Dial Transplant. 2009
  9. 24(10):3132-3137. [CrossRef] 9. Castano E, Palmer MB, Vigneault C, Luciano R, Wong S, Moeckel G. Comparison of amyloid deposition in human renal biopsies as predictor of poor patient outcome. BMC Nephrol. 2015
  10. [CrossRef] 10. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001
  11. 358(9275):24-29. [CrossRef] 11. Kuroda T, Tanabe N, Kobayashi D, et al. Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis. BMC Nephrol. 2012
  12. [CrossRef] 12. Yao Y, Wang SX, Zhang YK, Qu Z, Liu G, Zou WZ. A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. Nephrol Dial Transplant. 2013
  13. 28(3):689-697. [CrossRef] 13. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014
  14. 15(12):e538-e548. [CrossRef] 14. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009
  15. 150(9):604- 612. [CrossRef] 15. Buxbaum JN, Linke RP. A molecular hist